Leber- und Studienzentrum Checkpoint
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stulnig, Thomas M
COMBAT_T2_NASH, NCT04639414: Combined Active Treatment in Type 2 Diabetes with NASH

Active, not recruiting
4
192
Europe
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo
German Diabetes Center, Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
01/25
12/25
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting
2
138
Europe
Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg
Medical University of Graz, Juvenile Diabetes Research Foundation
Diabetes Mellitus, Type 1
05/25
05/26
TREASURE-CKD, NCT05536804 / 2021-005273-47: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
140
Europe, Canada, US, RoW
Tirzepatide, Placebo
Eli Lilly and Company, Eli Lilly and Company
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
01/26
02/26
NCT04277598: A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer

Completed
1/2
159
Europe, RoW
APO-2, Placebo
Aposcience AG, FGK Clinical Research GmbH
Diabetic Foot Ulcer (DFU)
12/23
12/23
Heyne, Renate
PBC-Cohort, NCT04076527 / 2016-004141-90: Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis

Recruiting
N/A
1200
Europe
UDCA, ursodeoxycholic acid, Ocaliva, obeticholic acid
University of Leipzig, RWTH Aachen University, Zentrum für Klinische Studien Leipzig, Intercept Pharma Europe Limited (IPEL), Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University Hospital Erlangen, Medical care center for Gastroenterology, Berlin, Institute for Interdisciplinary Medicine, Hamburg, Leberhilfe Projekt gUG, Cologne, Hannover Medical School
PBC, Primary Biliary Cholangitis
03/24
03/24
NCT04721665: German SLD-Registry (Deutsches SLD-Register)

Recruiting
N/A
5000
Europe
Leberstiftungs-GmbH Deutschland
Steatotic Liver Disease
11/26
11/36

Download Options